Ellis Sean's Form 4 filing
Entera Bio Ltd. (ENTX) · filed Jan 19, 2022
- Accession no.
- 0001178913-22-000163
- Filed
- Jan 19, 2022
- Trade date
- Jan 18, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $28.1K. It was filed 1 day after the trade.
This filing was later replaced by the amendment 0001178913-22-002767 (Jul 25, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ellis SeanCIK 0001904752 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 18, 2022 | Ordinary Shares, par value NIS 0.0000769 per share | PPurchaseAcquired | +10,000 | $2.81F1 | +$28,100 | 10,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.80 to $2.85, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.